-
1Academic Journal
Συγγραφείς: A. V. Tereshchenko, I. G. Trifanenkova, A. A. Vydrina, S. V. Isaev, А. В. Терещенко, И. Г. Трифаненкова, А. А. Выдрина, С. В. Исаев
Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 69, № 3 (2024); 86-93 ; Российский вестник перинатологии и педиатрии; Том 69, № 3 (2024); 86-93 ; 2500-2228 ; 1027-4065
Θεματικοί όροι: высокотехнологичное лечение, retinopathy of prematurity, perinatal center, ophthalmological center, high-tech treatment, ретинопатия недоношенных, перинатальный центр, офтальмологический центр
Περιγραφή αρχείου: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/2009/1499; Cao G., Liu J., Liu M. Global, Regional, and National Incidence and Mortality of Neonatal Preterm Birth, 1990-2019. JAMA Pediatr 2022; 8(176): 787-796. DOI:10.1001/jamapediatrics.2022.1622; Шилова Н.А., Харламова Н.В., Фисюк Ю.А., Чаша Т.Ю., Чуракова Е.В., Межинский С.С. Частота и исходы ретинопатии у глубоконедоношенных новорожденных в условиях оказания специализированной медицинской помощи. Российский вестник перинатологии и педиатрии 2018; 63(5): 51-54. 10.21508/1027-4065-2018-63-5-51-54; Kim S.J., Port A.D., Swan R., Campbell J.P. Chan R.V.P., Chiang M.F. Retinopathy of Prematurity: A Review of Risk Factors and their Clinical Significance. Surv Ophthalmol 2018; 63(5): 618-637. DOI:10.1016/j.survophthal.2018.04.002; Raghuveer T.S., Zackula R. Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis. Neoreviews 2020; 21(4): 249-263. DOI:10.1542/neo.21-4-e249; Chang E.T., Josan A.S., Purohit R., Patel C.K., Xue K.A. Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept and Laser for Retinopathy of Prematurity. Ophthalmology 2022; 129(12): 1389-1401. DOI:10.1016/j.ophtha.2022.06.042; Сахарова Е.С., Кешишян Е.С., Алямовская Г.А., Зиборова М.И. Недоношенность как медико-социальная проблема здравоохранения. Часть 2. Российский вестник перинатологии и педиатрии 2017; 62(4): 43-48. DOI:10.21508/1027-4065-2017-62-4-37-42; Daruich A., Bremond-Gignac D., Behar-Cohen F., Kermorvant E. Retinopathy of prematurity: from prevention to treatment. Med Sci (Paris) 2020; 36(4): 900-907. DOI:10.1051/ medsci/2020163; Dammann O., Hartnett M.E., Stahi A. Retinopathy of prematurity. Dev Med Child Neurol 2023; 65(5): 625-631. DOI:10.1111/dmcn.15468; Ahmed S.B., Higham A., Mulvihill A., Chan T.KJ., Adams G., Patel C.K. The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity. Eye (Lond) 2021; 35(9): 2451- 2453. DOI:10.1038/s41433-021-01543-9; Tran K.D., Cernichiaro-Espinosa L.A., Berrocal A.M. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy. Asia Pac J Ophtalmol (Phila) 2018; 7(1): 56-62. DOI:10.22608/APO.2017436; Gundlach B.S., Kokhanov A., Altendahi M., Sun S.Y., Fung S., Demer J. et al. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity. Am J Ophthalmol 2022; 238: 86-96. DOI:10.1016/j.ajo.2021.11.015; Barnett J.M., Hubbard G.B. Complications of Retinopathy of Prematurity Treatment. Curr Opin Ophthalmol 2021; 32(5): 475-481. DOI:10.1097/ICU.0000000000000783; Tsiropoulos G.N., Seliniotaki A.K., Haidich A.B., Ziakas N., Mataftsi A. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review. Int Ophthalmol 2023; 43(3): 1027-1062. DOI:10.1007/s10792-022-02480-6; Stahl A., Suken E., Wu W.C., Lepore D., Nakanishi H., Mazela J. et al. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The Firefleye Randomized Clinical Trial. JAMA 2022; 4(328): 248-359. DOI:10.1001/jama.2022.10564; Сидоренко Е.Е., Николаева Г.В., Сидоренко Е.И. Применение ингибитора сосудистого эндотелиального фактора роста при аномальной пролиферативной ангиоретинопатии у недоношенного ребенка. Вестник оренбургского государственного университета 2014; 12(173): 240-243.; Исаев С.В., Новикова М.В. Оптимизация мониторинга недоношенных детей в условиях современных высокотехнологичных перинатальных центров. Современные технологии в офтальмологии 2020; 4(35): 211-212. DOI:10.25276/2312-4911-2020-4-211-212; World Health Organization. Preterm birth. Published February 19, 2018. Accessed January 1, 2022. https://www.who.int/news-room/fact-sheets/detail/preterm-birth / Ссылка активна на 22.02.2024.; Chawanpaiboon S., Vogel J.P., Moller A.B., Lumbiganon P., Petzold M., Hogan D. et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health 2019; 7(1): e37-e46. DOI:10.1016/S2214-109X(18)30451-0; Goldenberg R.L., Culhane J.F., Iams J.D., Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371(9606): 75-84. DOI:10.1016/S0140-6736(08)60074-4; Seiberth V., Linderkamp O. Risk factors in retinopathy of prematurity. A multivariate statistical analysis. Ophthalmologica 2000; 214(2): 131-135. DOI:10.1159/000027482; Quinn G. Retinopathy of prematurity blindness worldwide: phenotypes in the third epidemic. Eye and Brain 2016; 8: 31- 36. DOI:10.2147/EB.S94436; Chan H., Cougnard-Grégoire A., Korobelnik J.F., Delyfer M.N., Touboul D., Coste V. et al. Screening for retinopathy of prematurity by telemedicine in a tertiary level neonatal intensive care unit in France: review of a six-year period. J Fr Ophtalmol 2018; 41: 926-932. DOI:10.1016/j.jfo.2018.02.020; Holmström G., Tornqvist K., Al-Hawasi A., Nilsson Å., Wallin A., Hellström A. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta Ophthalmol 2018; 96(2): 142-148. DOI:10.1111/aos.13549; Venincasa V.D., Bugg V., Dvorak J., Ding K., Bhatti F., Siatkowski R.M. Temporal profile of retinopathy of prematurity in extremely premature compared to premature infants. J Pediatr Ophthalmol Strabismus 2019; 56(2): 116-123. DOI:10.3928/01913913-20190205-01; Chang E., Josan A.S., Purohit R., Patel C.K., Xue K. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity. Ophthalmology 2022; 129(12): 1389-1401. DOI:10.1016/j.ophtha.2022.06.042; Stahl A., Sukgen E.A., Wu W.C. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA 2022; 328(4): 348-359. DOI:10.1001/jama.2022.10564; Wood E.H., Chang E.Y., Beck K., Hadfield B., Quinn A., Harper 3rd C. et al. 80 Years of vision: preventing blindness from retinopathy of prematurity. J Perinatol 2021; 41(6): 1216- 1224. DOI:10.1038/s41372-021-01015-8; Gunay M., Sukgen E.A., Celik G., Kocluk Y. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. Curr Eye Res 2017; 42(3): 462-469. DOI:10.1080/02713683.2016.1196709; Chow S.C., Lam P.Y., Lam W.C., Fung N.S.K. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review. Eye (Lond) 2022; 36(8): 1532-1545. DOI:10.1038/s41433-021-01922-2; Sankar M.J., Sankar J., Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2018; 1(1): CD009734. DOI:10.1002/14651858; Sato T., Wada K., Arahori H., Kuno N., Imoto K., Iwahashi-Shima C., Kusaka S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153(2): 327-333. DOI:10.1016/j.ajo.2011.07.005